CN100488512C - 用于治疗细胞增殖性紊乱的组合物及其用途 - Google Patents

用于治疗细胞增殖性紊乱的组合物及其用途 Download PDF

Info

Publication number
CN100488512C
CN100488512C CNB998163155A CN99816315A CN100488512C CN 100488512 C CN100488512 C CN 100488512C CN B998163155 A CNB998163155 A CN B998163155A CN 99816315 A CN99816315 A CN 99816315A CN 100488512 C CN100488512 C CN 100488512C
Authority
CN
China
Prior art keywords
glcnac
composition
endothelin
endothelin antagonist
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998163155A
Other languages
English (en)
Chinese (zh)
Other versions
CN1335749A (zh
Inventor
J·N·沃尔纳基斯
S芬基斯茨坦
E·R·帕里泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Publication of CN1335749A publication Critical patent/CN1335749A/zh
Application granted granted Critical
Publication of CN100488512C publication Critical patent/CN100488512C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/042Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/70Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
CNB998163155A 1998-12-22 1999-12-21 用于治疗细胞增殖性紊乱的组合物及其用途 Expired - Lifetime CN100488512C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/218,288 US6063911A (en) 1993-12-01 1998-12-22 Methods and compositions for treatment of cell proliferative disorders
US09/218,288 1998-12-22

Publications (2)

Publication Number Publication Date
CN1335749A CN1335749A (zh) 2002-02-13
CN100488512C true CN100488512C (zh) 2009-05-20

Family

ID=22814511

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998163155A Expired - Lifetime CN100488512C (zh) 1998-12-22 1999-12-21 用于治疗细胞增殖性紊乱的组合物及其用途

Country Status (14)

Country Link
US (1) US6063911A (enExample)
EP (1) EP1139752B1 (enExample)
JP (1) JP4795539B2 (enExample)
CN (1) CN100488512C (enExample)
AT (1) ATE294504T1 (enExample)
AU (1) AU780248B2 (enExample)
CA (1) CA2356087C (enExample)
DE (1) DE69925156T2 (enExample)
ES (1) ES2242448T3 (enExample)
HK (1) HK1043507B (enExample)
IL (2) IL143700A0 (enExample)
NO (1) NO330033B1 (enExample)
NZ (1) NZ512586A (enExample)
WO (1) WO2000036918A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
IL150311A0 (en) 1999-12-31 2002-12-01 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
PL366419A1 (en) * 2000-08-22 2005-01-24 Boehringer Ingelheim Pharma Bmbh & Co.Kg Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
EP1587424A4 (en) * 2002-12-31 2012-01-25 Marinepolymer Tech Inc Bleeding Compounds and their uses
KR20050098250A (ko) * 2003-01-17 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 에너골리틱제를 사용한 양성 전립선 비대증의 치료 방법
NZ542501A (en) * 2003-02-24 2009-09-25 Marinepolymer Tech Inc Compositions comprising chitin or chitosan and use thereof
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
EP1673134A4 (en) * 2003-09-12 2007-03-21 Marinepolymer Tech Inc RECEIVING VASCULAR ACCESS IN HEMODIALYSIS PATIENTS
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP1734821A4 (en) * 2004-04-14 2011-07-06 Uab Research Foundation ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化IL−15およびIL−15R−α遺伝子
US8871247B2 (en) * 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
AU2008269032B2 (en) 2007-06-27 2013-12-05 Novartis Ag Complexes of IL-15 and IL-15Ralpha and uses thereof
US9539327B2 (en) * 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
CA2796068C (en) 2010-04-15 2022-07-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
GB201616087D0 (en) * 2016-09-21 2016-11-02 Tomalgae Cvba Algae comprising therapeutic and/or nutritional agents
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86106428A (zh) * 1985-09-23 1987-03-18 伊莱利利公司 抗肿瘤方法及其化合物
US5541186A (en) * 1993-06-28 1996-07-30 Hoffmann-La Roche Inc. Sulfonylaminopyrimidines
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5641752A (en) * 1991-05-16 1997-06-24 Warner-Lambert Company Methods of using endothelin antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) * 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3988411A (en) * 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
US3989535A (en) * 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
JPS55152705A (en) * 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
US4378017A (en) * 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
US4803168A (en) * 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPS62288602A (ja) * 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5071977A (en) * 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
US5116747A (en) * 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04334322A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 抗腫瘍剤
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
US5219749A (en) * 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
WO1993009176A2 (en) * 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
ES2164054T3 (es) * 1991-11-05 2002-02-16 Smithkline Beecham Corp Antagonistas de receptores de endotelina.
IL100096A (en) * 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5624679A (en) * 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (enExample) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
WO1996039122A1 (en) * 1995-06-06 1996-12-12 Marine Polymer Technologies, Inc. POLY-β-1→4-N-ACETYLGLUCOSAMINE
AU6603996A (en) * 1995-08-24 1997-03-19 Warner-Lambert Company Furanone endothelin antagonists
AU2529297A (en) * 1996-04-10 1997-10-29 Warner-Lambert Company Ketoacid endothelin antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86106428A (zh) * 1985-09-23 1987-03-18 伊莱利利公司 抗肿瘤方法及其化合物
US5641752A (en) * 1991-05-16 1997-06-24 Warner-Lambert Company Methods of using endothelin antagonists
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5541186A (en) * 1993-06-28 1996-07-30 Hoffmann-La Roche Inc. Sulfonylaminopyrimidines
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5623064A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Poly-β-1→-4-N-acetylglucosamine

Also Published As

Publication number Publication date
JP4795539B2 (ja) 2011-10-19
EP1139752B1 (en) 2005-05-04
NO20013071D0 (no) 2001-06-20
AU2591900A (en) 2000-07-12
CA2356087A1 (en) 2000-06-29
US6063911A (en) 2000-05-16
AU780248B2 (en) 2005-03-10
IL143700A (en) 2006-08-01
ES2242448T3 (es) 2005-11-01
HK1043507B (zh) 2009-12-24
WO2000036918A9 (en) 2000-11-23
NO20013071L (no) 2001-08-20
DE69925156T2 (de) 2006-02-16
IL143700A0 (en) 2002-04-21
NZ512586A (en) 2004-01-30
DE69925156D1 (de) 2005-06-09
CN1335749A (zh) 2002-02-13
CA2356087C (en) 2009-02-17
JP2003522732A (ja) 2003-07-29
NO330033B1 (no) 2011-02-07
HK1043507A1 (zh) 2002-09-20
ATE294504T1 (de) 2005-05-15
EP1139752A4 (en) 2003-01-02
WO2000036918A1 (en) 2000-06-29
EP1139752A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
CN100488512C (zh) 用于治疗细胞增殖性紊乱的组合物及其用途
Bashir et al. N-succinyl chitosan preparation, characterization, properties and biomedical applications: A state of the art review
Vercruysse et al. Hyaluronate derivatives in drug delivery
US6610668B2 (en) Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US20090247738A1 (en) Biocompatible poly-beta-1-4-n-acetylglucosamine
EP1619210A1 (en) DDS compounds and method for assaying the same
ES2222740T3 (es) Polimeros mucoadhesivos, uso y procedimiento de preparacion de los mismos.
US5624679A (en) Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
Prestwich Biomaterials from chemically-modified hyaluronan
Giri et al. Polysaccharide Hydrogels for Drug Delivery and Regenerative Medicine
ES2874075T3 (es) Nuevos hidrogeles de estructura sililada y procedimiento de obtención
MXPA01006483A (en) Methods and compositions for treatment of cell proliferative disorders
PROFIRE et al. Sulfadiazine modified CS/HA PEC destined to wound dressing
Yurkshtovich et al. Starch phosphate microgels for controlled release of biomacromolecules
Cui et al. Chitosan: a versatile biomedical polymer
Musale et al. CHITOSAN AND THIOLATED CHITOSAN DERIVATIVES: A BRIEF
WO2025231476A1 (en) Method for coating a cell with a biomimetic zona pellucida
Sakeer Starch derivatives as carriers for bioactive agents
KR20080026259A (ko) 약물 전달체로 사용되는 풀루란 아세테이트, 그의 미립구및 그들의 제조방법
JPWO2000025825A1 (ja) Dds化合物及びその測定方法

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1043507

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20090520

CX01 Expiry of patent term